471. The Rochester Regional COVID-19 Registry: One Small Step toward a Unified National Action Plan

BACKGROUND: On June 19, 2020, the Academies of Sciences, Engineering, and Medicine hosted a public meeting on “Data Needs to Monitor the Evolution of SARS-CoV-2”. The Office of the Assistant Secretary for Preparedness and Response (ASPR/HHS) and other agencies are seeking to track and correlate viral genome sequences with clinical and epidemiological (CE) data. A crucial part of that framework is obtaining detailed CE data from frontline facilities. In response, we sought to contribute by creating a registry of detailed CE data from SARS-COV -2 infected patients at five hospitals, spanning eleven counties in Western New York. METHODS: In addition to the usual demographics, comorbidities, and categories of outpatient prescriptions, the registry has 75 laboratory, 2 imaging, 19 therapeutic, and 4 outcome-related parameters. Mann-Whitney U Test for continuous variables and Chi-squared and Fisher Exact Test for categorical variables were performed in R and Minitab. RESULTS: The registry currently includes data from 399 patients: 236 ambulatory and 163 inpatient. Several comorbidities were associated with requirement for admission compared to ambulatory status, including obesity and kidney, liver, and cardiovascular disease (all p < /= 0.01) (Table 1). Use of angiotensin inhibitors and receptor blockers, statins, and acid suppressants was higher in admitted vs. ambulatory patients (all p < /=0.001) (Table 1 and Figure). Diabetes mellitus and statin use were more common in patients who required intensive care, p=0.04 and 0.01 respectively (Table 2). Table 1 [Image: see text] Figure [Image: see text] Table 2 [Image: see text] CONCLUSION: The registry captures detailed clinical information from SARS-COV-2 infections, providing a valuable resource for researchers, planners, and policy makers. It also provides a framework for surge planning, predictive modeling, and linking CE data to whole genome sequencing data for precision epidemiology. As SARS-COV-2 reports from China, Italy, and New York City may not be fully generalizable to other regions, especially those not as severely affected or those in suburban and rural settings, reports from other areas are needed. To our knowledge, this is one of the largest U.S. case series outside of New York City. DISCLOSURES: All Authors: No reported disclosures